Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. FDA allows 23andMe to sell test for 3 mutations of breast cancer gene

The U.S. Food and Drug Administration on Tuesday allowed genetic testing company 23andMe to market directly to consumers its test that will help assess three mutations in a common type of breast cancer gene.

Read More »

FDA to Review Dupixent for Severe Asthma

The U.S. FDA accepted for review the supplemental BLA of Dupixent (dupilumab) as an add-on maintenance treatment in certain adults and adolescents with moderate-to-severe asthma.

Read More »

Teva’s Shrinking U.S. Footprint

Teva Pharmaceuticals Inc. made more cuts in the United States, this time to real estate holdings. To save money, the company will close its offices in Washington, D.C. and New York City. No jobs were reported to be lost from the cuts.

Read More »

FDA Grants Evofem’s Amphora Fast Track Designation

The U.S. FDA granted San Diego-based Evofem Biosciences Fast Track designation for Amphora vaginal gel to prevent urogenital chlamydia infection in women.

Read More »

11 Most Innovative Life Science Companies in the World

Fast Company recently published The World’s 50 Most Innovative Companies 2018, topping off its edition of the top 350 most innovative companies. Here is a look at the life science companies that made the list.

Read More »

AbbVie, Voyager Launch Alzheimer’s Partnership

Chicago-based AbbVie and Cambridge, Mass.-based Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.

Read More »

Aimmune’s peanut allergy drug meets main goal

U.S. drug developer Aimmune Therapeutics Inc.’s peanut allergy drug met the main goal of an eagerly awaited late-stage study.

Read More »

Eli Lilly and Hanmi Shutter a Failed Phase II RA Trial

Eli Lilly and its Korean collaborative partner Hanmi Pharmaceutical stopped a Phase II trial on an experimental rheumatoid arthritis treatment after less-than-stellar interim results were examined.

Read More »

FDA Advisory Panel Spurns Pacira’s Request for Expanded Use of Pain Drug Exparel

Shares of Pacira Pharmaceuticals plunged more than 15 percent after the company revealed a U.S. Food and Drug Administration advisory panel recommended against approving expanded use of the company’s pain treatment Exparel.

Read More »

U.S. FDA looks to pave way for earlier-stage Alzheimer’s drugs

U.S. regulators proposed lowering the bar for clinical trial success for experimental Alzheimer’s drugs.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom